AU4148999A - Creation of Inventions and Patents with Artificial Intelligence

AU4148999A – Hiv virus mimotopes
– Google Patents

AU4148999A – Hiv virus mimotopes
– Google Patents
Hiv virus mimotopes

Download PDF
Info

Publication number
AU4148999A

AU4148999A
AU41489/99A
AU4148999A
AU4148999A
AU 4148999 A
AU4148999 A
AU 4148999A
AU 41489/99 A
AU41489/99 A
AU 41489/99A
AU 4148999 A
AU4148999 A
AU 4148999A
AU 4148999 A
AU4148999 A
AU 4148999A
Authority
AU
Australia
Prior art keywords
peptide
seq
phe
thr
ala
Prior art date
1998-06-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Application number
AU41489/99A
Other versions

AU748700B2
(en

Inventor
Veronique Barban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi Pasteur SA

Original Assignee
Pasteur Merieux Serum et Vaccines SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1998-06-12
Filing date
1999-06-14
Publication date
2000-01-05

1999-06-14
Application filed by Pasteur Merieux Serum et Vaccines SA
filed
Critical
Pasteur Merieux Serum et Vaccines SA

2000-01-05
Publication of AU4148999A
publication
Critical
patent/AU4148999A/en

2002-06-13
Application granted
granted
Critical

2002-06-13
Publication of AU748700B2
publication
Critical
patent/AU748700B2/en

2019-06-14
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K39/00—Medicinal preparations containing antigens or antibodies

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K2319/00—Fusion polypeptide

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N2740/00—Reverse transcribing RNA viruses

C12N2740/00011—Details

C12N2740/10011—Retroviridae

C12N2740/16011—Human Immunodeficiency Virus, HIV

C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env

C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Description

WO 99/66046 PCT/FR99/01 4 09 Mimotopes of the HIV virus Subject of the invention The present invention relates to the treatment 5 and prevention of the HIV virus and in particular to any peptide mimicking novel conformational epitopes of antigens of the HIV virus envelope and to any polynucleotide integrated into a vector allowing the expression of said peptides and their use for 10 therapeutic, prophylactic, in particular vaccine, and/or diagnostic purposes. Field of the invention HIV is an enveloped RNA virus and represents the etiological agent of the acquired immunodeficiency 15 syndrome or AIDS, whose outcome is ultimately fatal, characterized by a progressive destruction of the immune system and the concomitant development of microbiological infections often involving opportunistic microorganisms. 20 The majority of individuals develop an acquired immunodeficiency syndrome within 10 years following infection. Indeed, the immune reactions in response to the infection are very often inadequate and in particular those which are directed against the 25 envelope proteins precisely because of the very high variability of the virus resulting from its high capacity to multiply, to mutate and to recombine (Bangham C.R.M. et al 1997 Lancet 350: 1617-1621) . The very high variability of the HIV virus makes it 30 possible to escape control by the immune system and thus promotes dissemination of the virus. However, recent epidemiological studies have shown that some infected persons could contain their infection, with no apparent clinical manifestations and with no biological 35 signs of immunosuppression for periods of longer than RA 10 years (Pilgrim A.K. et a., 1997, J. Infect. Dis. 176: 924-932) . The serum of these persons, also called S”long-term nonprogressors”, reveals the presence of -2 neutralizing antibodies against primary isolates of the HIV virus (Pilgrim A.K. et al., 1997, J. Infect. Dis. 176: 924-932). The HIV virus envelope, derived from the 5 product of expression of the Env gene (envelope gene), is synthesized first of all in the form of a glycoprotein Gp160 which is then cleaved into two glycoproteins Gp 120 and Gp 41. These 3 proteins are found at the surface of cells infected with HIV. 10 Furthermore, Gp 160 and Gp 120 possess affinity for the CD4 molecule present at the surface of certain T lymphocytes, a CD4 molecule which serves as port of entry for the HIV virus toward the inside of the cell. Up until now, very few epitopes accessible to the 15 immune system have been described on the HIV virus envelope (Burton D.R, 1997 Proc. Natl. Acad. Sci. USA 94: 10018-10023). A need therefore exists for the charac terization of novel epitopes of the HIV envelope. 20 A need also exists to identify epitopes of the envelope which are inducers of neutralizing antibodies, or in other words, which are capable of reducing or suppressing viral dissemination. A need also exists to identify a pharmaceutical 25 composition which makes it possible to effectively treat or to prevent HIV virus infection. Finally, a need also exists to develop reagents entering in particular into the composition of immunological kits which make it possible to 30 distinguish in particular among infected persons those which are most resistant to infection or “long-term nonprogressors” and to test, for example, the efficacy of novel vaccines by their capacity to induce neutralizing antibodies. 35 Summary of the invention The present invention aims to satisfy these needs by identifying novel peptide structures for the RAg therapeutic or prophylactic treatment of HIV virus infection from the use of a combinatorial antibody -3 library obtained from HIV-positive patients belonging to the “long-term nonprogressor” group. To this effect, the invention relates to any peptide structure capable of reacting with an antibody specific for an antigen of 5 the HIV envelope derived, for example, from a combinatorial antibody library obtained from lymphocytes of HIV-positive patients belonging to the “long-term nonprogressor” group, comprising an amino acid sequence which mimics a conformational epitope of 10 the envelope of said virus without, however, corresponding to a continuous amino acid sequence of this antigen. The selection of mimotopes by means of recombinant antibodies obtained from HIV-positive 15 patients belonging to the “long-term nonprogressor” group has the advantage of identifying novel epitopes inducing neutralizing antibodies which are effective in protecting against primary HIV virus isolates. The present invention also relates to any 20 recombinant vector comprising a functional expression cassette allowing the expression of a polynucleotide encoding a peptide meeting the criteria defined above. The present invention also relates to a therapeutic or prophylactic composition for the HIV 25 virus, in particular intended for vaccine use, whose active ingredient comprises a peptide meeting the criteria defined above and/or a recombinant vector encoding said peptide. Finally, the present invention also relates to 30 – the use of a peptide meeting the criteria defined above as reagent for the diagnosis of the HIV virus which makes it possible in particular to identify subjects in contact with the virus who are more resistant to infection, said diagnosis comprising the 35 evaluation, from a blood sample, of the humoral and/or cell-mediated response specific for this peptide; – the use of a peptide meeting the criteria defined above and/or of a recombinant vector encoding said peptide for the preparation of a therapeutic or -4 prophylactic composition intended for the treatment or prevention of HIV virus infection. Description of the invention In the context of the present invention, 5 various terms used are defined below: The expression “peptide” is understood to mean a sequence of at least 6 amino acids linked to each other by a peptide bond, obtained by chemical synthesis or by genetic recombination techniques, preferably 10 between 6 and 100 amino acids and in particular between 20 and 80 amino acids. The expression “antigen of the HIV envelope” is understood to mean any molecular entity which binds to an antibody specific for any product derived from the 15 env gene, comprising in particular gp 160 in natural or recombinant form, its derivatives consisting of gp4l and gp 120 which may also be in natural or recombinant form and the products derived from the combination of said molecules. 20 The expression “conformational epitope” is understood to mean a three-dimensional structure which allows its positioning in the specific binding site of an antibody, in the manner of a key in a lock, and which is represented by an amino acid sequence which 25 does not correspond to a continuous amino acid sequence of the protein against which this antibody is directed. Preferably, this amino acid sequence of the conformational epitope is not homologous to a continuous amino acid sequence of the natural or 30 recombinant protein, the homology being defined by the combination of two criteria: – the amino acid identity criterion determined by the ratio between the number of amino acids of a peptide according to the invention which are 35 identical to those of a sequence of the same size carried by the natural or recombinant protein, and the total number of amino acids of said peptide. Preferably, the amino acid identity will 4Lu -5 preferably not exceed 50%, even 60% or 70% or 80% or even 90%; – the linkage criterion determined by the ratio between the number of amino acids of a peptide 5 according to the invention which are both identical and are present in the same linkage position as those of a sequence of the same size carried by the natural or recombinant protein, and the total number of amino acids of said peptide. 10 Preferably, the linkage identity will not exceed 70 to 80%. The term “long-term nonprogressor” is understood to mean HIV-positive subjects characterized from the clinical point of view in that they have not 15 developed AIDS since they were infected over a period of at least ten years, from the biological point of view in that they do not show signs of immunosuppression with in particular a level of CD4 T lymphocytes greater than 600/mm 3 and finally who are 20 not receiving a particular antiviral treatment. The expression “mimotope” is understood to mean an epitope which mimics the three-dimensional structure of another epitope by binding to the specific binding site of the same antibody. 25 The expression “CDR3” is understood to mean the hypervariable region of the linkage of amino acids of the heavy and light immunoglobulin chains which is situated at the level of the specific site for interaction with the epitope. 30 The expression “conjugate” is understood to mean the combination of the peptide as defined in the invention with any other molecule, by physical or chemical processes, intended to induce or enhance the immunogenicity of the initial peptide. 35 The expression “immunogenicity” is understood to mean the capacity of a molecular entity, after inoculation into a mammal, to induce a production of antibody specifically directed against this entity. 1 -6 The expression “polynucleotide” is understood to mean either an RNA sequence, or a DNA sequence, or a cDNA sequence resulting from the reverse transcription of a sequence of natural or synthetic origin, with or 5 without modified bases. The expression “mucosal route” is understood to mean a mode of administration which brings the pharmaceutical composition directly into contact with the various types of mucous membranes of the body. 10 The expression “parenteral route” is understood to mean a mode of administration which brings the pharmaceutical composition directly into contact with the internal tissues or organs of the body. The invention is therefore aimed at any peptide 15 which mimics a conformational epitope of an antigen of the HIV envelope and which is recognized by an antibody obtained from a “long-term nonprogressor” patient and specific for this antigen. A peptide according to the invention may be advantageously represented by one of 20 the 11 sequences as follows SEQ ID NO: 1 Phe Asn Leu Thr His Phe Leu SEQ ID NO: 2 Glu Gly Trp His Ala His Thr SEQ ID NO: 3 Lys Leu Asn Trp Met Phe Thr 25 SEQ ID NO: 4 Ser Thr Asn Trp Met Phe Thr SEQ ID NO: 5 Ala Met Pro Leu Pro Tyr Thr Phe SEQ ID NO: 6 Asp Ser His Thr Pro Gln Arg SEQ ID NO: 7 Val Ser Phe Thr Pro Ser Phe SEQ ID NO: 8 His Ala Ala Leu Ser Met Asn Thr His Ala Leu Met 30 SEQ ID NO: 9 Ala Trp His Glu Ser Arg Ala SEQ ID NO: 10 Phe Lys Thr Ala Tyr Pro Thr SEQ ID NO: 11 Ser His Ala Leu Pro Leu Thr Trp Ser Thr Ala Ala From a combinatorial antibody library obtained 35 in particular from peripheral blood of a subject who has been infected with the HIV virus and belongs to the “long-term nonprogressor” group, characterized in that said subject belonging to this group has been asymptomatic from the clinical point of view for at -7 least 10 years and shows no biological signs of immunosuppression with in particular a level of CD4 T lymphocytes greater than 600/mm 3 , and from a synthetic peptide library, it is possible to identify, by means 5 of mimotopes, novel conformational epitopes present on the HIV envelope, in particular epitopes which may be located outside the V3 loop, such as for example epitopes located in the region of the site for binding to the CD4 receptor, epitopes overlapping the V2 loop 10 and the site for binding to the CD4 receptor or even epitopes overlapping the C2, C3 and V4 regions of Gp120 or epitopes located in the noninmunodominant regions of Gp4l (clusters I and II) . The identification of these mimotopes requires, for their use, a sophisticated 15 technological process, namely: – the preparation of a combinatorial antibody library which is sufficiently complex to better reflect the natural antibody repertoire of one individual, and advantageously the antibody repertoire of an individual 20 infected with HIV and belonging to the “long-term nonprogressor” group; – the selection, from this library, of recombinant antibodies specific for antigens of the HIV envelope, in particular expressed by Gpl60, Gp120, Gp4l which may 25 be in the form of natural or recombinant, glycosylated or deglycosylated, monomeric or multimeric proteins or finally of proteins combined with each other or otherwise. The selection of specific recombinant antibodies preferably comprises an additional step 30 consisting in measuring the neutralizing activity of these recombinant antibodies toward the viral infection mediated in particular by one or more primary HIV virus isolates. The recombinant antibodies specific for and neutralizing several primary HIV virus isolates will be 35 preferably selected; – the selection of peptides specific for the recombinant antibodies, from a random synthetic peptide cRA41 R ‘ library obtained by molecular recombination, it being possible to carry out said selection by ELISA; -o e ZA -8 – the characterization of these peptides as being mimotopes of conformational epitopes of HIV in that there is no correspondence between the amino acid sequence of said peptide with any continuous amino acid 5 sequence found in the proteins of the HIV envelope, on the one hand, and, on the other hand, in that this peptide is capable of inhibiting the interaction of the recombinant antibody with the product of the env gene which served for the selection of said recombinant 10 antibody. It is also possible to carry out the transformation of lymphocytes obtained from a “long term nonprogressor” patient using, for example, the Epstein-Barr virus (EBV) for the selection of novel 15 monoclonal antibodies specific for the HIV envelope. The method for lymphocyte transformation is well known to a person skilled in the art and results, after several cycles of selection against the antigen of interest, in the production of transformed and immortal 20 lymphocyte clones, each clone producing a single type of monoclonal antibody. These monoclonal antibodies, like the recombinant antibodies derived from the combinatorial library, may also be tested for their neutralizing activity against various primary HIV 25 isolates before being used for the selection of mimotope peptides of the HIV envelope. To induce or rather enhance the immunogenicity of the peptide mimicking a conformational HIV epitope, the subject of the present invention is also peptides 30 comprising a repetition (2 or more) of the peptide in accordance with the invention. In particular, the coupling of the two identical peptides may be performed, if necessary, by means of an intercalating spacer arm consisting of the linkage of amino acids Gly 35 Pro Gly. The invention also relates to a combination of various peptides in accordance with the invention, as RA4/ well as to peptides comprising both repetitions and combinations.
-9 In such cases, the peptides may be joined by covalent bonds or noncovalent bonds. For example, there may be advantageously mentioned the method developed by Posnett et al (J. Biol. Chem. (1988) 263: 1719) which 5 does not alter the three-dimensional structure of the epitope or of the epitopes carried by the peptide and results in the formation of multimers of the same peptide or of different peptides. In the context in particular of antigenic 10 preparations and of vaccine formulations which are described below, it is also possible to prefer conjugating, through covalent bonding, the peptides of the invention with immunogenic molecules customarily used for making small-sized peptides immunogenic. 15 The peptides according to the invention may thus be conjugated with known immunogenic proteins such as serum albumins, thyroglobulin, ovalbumin, gelatin, hemocyanin (e.g. Keyhole Limpet Hemocyanin KLH), seroglobulins, tetanus toxoid, diphtheria toxoid, 20 bacterial outer membrane proteins, and the like, but it is also possible to prefer conjugating the peptides with “helper T” epitopes among which there may be chosen in particular the HIV “helper T” epitopes, for example the T1 and p24E epitopes as described in 25 WO 94/29339 (Connaught). The reactions for conjugation with said HIV “helper T” epitopes allow us to obtain compounds whose sequential linkage is p24E-GPG-X-GPG-Tl where: – p24E symbolizes the amino acid sequence of the 30 epitope p24E, said sequence being placed on the N-terminal side of the peptide according to the invention; – GPG symbolizes the glycine-proline-glycine linkage; – X symbolizes the peptide of interest according to the 35 invention which maybe, if necessary, the product of the combination of several identical or different amino acid sequences in accordance with the invention; – 10 – T1 symbolizes the amino acid sequence of the epitope Ti, said sequence being placed on the C-terminal side of the peptide according to the invention. Among these compounds, there may be mentioned 5 the compounds comprising the sequences 12 to 14 SEQ ID NO: 12 Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Gly Pro Gly Lys Leu Asn Trp Met Phe Thr Gly Pro Gly Lys Leu Asn Trp Met Phe Thr Gly Pro Gly Iys Gln 10 Ile Ile Asn Met Trp Gln Glu Val Glu Lys Ala Met Tyr Ala SEQ ID NO: 13 Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Gly Pro Gly Ser Thr 15 Asn Trp Met Phe Thr Gly Pro Gly Ser Thr Asn Trp Met Phe Thr Gly Pro Gly Iys Gln Ile Ile Asn Met Trp Gln Glu Val Glu Lys Ala Met Tyr Ala 20 SEQ ID NO: 14 Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Gly Pro Gly Phe Asn Leu Thr His Phe Leu Gly Pro Gly Phe Asn Leu Thr His Phe Leu Gly Pro Gly Lys Gln Ile Ile Asn Met Trp Gln Glu Val Glu Lys 25 Ala Met Tyr Ala These conjugates can themselves be grafted onto a branched lysine backbone so as to obtain polymers of said conjugates in branched form as described in WO 94/29339 (Connaught), the technical content of said 30 patent being incorporated by reference into the subject-matter of the invention. The techniques for conjugation are also perfectly known to persons skilled in the art. There may be used, for example, heterobifunctional agents 35 such as SPDP, carbodiimide, glutaraldehyde, biotin/avidin system, and the like. It is also possible to couple the peptides to lipopolysaccharides, polysaccharides, glycopeptides, muramyl peptide analogs, fatty acids, and the like.
– 11 Preferably, the coupling of a peptide with a fatty acid of the type comprising palmitoyl-lysine as described in EP 491628 (Biovector) or (Pam)3 Cys-Ser as described in EP547681 (Merck) for example, the technical content of 5 said patents being incorporated by reference into the subject-matter of the invention. The methods for operably linking individual peptides by side chains carrying amino acid residues, in order to form an immunogenic conjugate, for example 10 a branched polypeptide polymer, are also well known to persons skilled in the art. By these methods, it is sought to establish bonds on various side chains by one or more types of functional groups in order to obtain a structure in which the peptide structures are 15 covalently linked while being separated by at least one side chain. As functional groups, there may be mentioned the epsilon-amino groups, beta- or gamma-carboxylic groups, thiol (-SH) groups and aromatic rings (for example tyrosine and histidine). 20 Methods for binding polypeptides with the aid of these functional groups are described in Erlanger (1980 Method of Enzymology, 70: 85), Aurameas et al., (1978 Scand. J. Immunol., Vol. 8, suppl. 7, 7-23) and US-A-4 193 795. In addition, it is also possible to use a 25 directed coupling reaction as described in Rodwell et al., (1985 Biotech 3, 889-894). The peptides may also be modified in order to incorporate spacer arms such as hexamethylenediamine or other bifunctional molecules of similar sizes. 30 The peptides may also be formulated with alum, monophosphoryl Lipid A, pluronics, SAF1, Ribi, trehalose-6,6-dimycolate or other immunostimulatory compounds known to persons skilled in the art to increase the immunogenicity of the peptide to which 35 these compounds are bound. However, all these methods of conjugation, modification, repetition or combination of peptides in accordance with the invention must observe the original conformation of the peptide as much as possible.
LIU
– 12 The subject of the present invention is also the DNA fragments encoding the peptides according to the invention and which can be used to produce the peptides by expression of the DNA sequence in an 5 appropriate expression system. By taking into account the degeneracy of the code, persons skilled in the art are perfectly capable of determining the various DNA sequences capable of encoding the various peptides in accordance with the invention. 10 According to a first aspect of the invention, the expression system is an in vitro expression system for the production of the peptides for their subsequent use, e.g. as diagnostic reagent, as antigenic component or as vaccine component. Such in vitro expression 15 systems or vectors are perfectly known to persons skilled in the art and there may be mentioned by way of example bacteria such as E. coli, eukaryotic cells such as yeasts, in particular S. cerevisiae, baculovirus, in particular propagated on insect cells, and the like. 20 The subject of the invention is therefore also an expression cassette comprising such a DNA fragment and regulatory sequences allowing the expression of this DNA fragment in an appropriate in vitro expression system. 25 According to a second aspect of the invention, the expression system is an in vivo expression system for generating a preferably protective immune response in the treated patient. In other words, the expression system, which may be replicative or nonreplicative, 30 will express the peptide in vivo. Persons skilled in the art have such systems at their disposal. By way of preferred examples, there may be mentioned plasmids, in particular naked plasmids, e.g. according to WO-A 90 11092, WO-A-93 19813, WO-A-94 21797 and WO-A 35 95 20660, poxviruses, such as the vaccinia virus and avian poxviruses (fowlpox, pigeonpox, canarypox, and the like), adenoviruses, and the like. The subject of the invention is therefore also $.\)expression cassettes comprising such a DNA fragment and – 13 the means for regulating expression in the chosen expression system. Its subject is also the expression system or expression vector, comprising such an expression cassette, in particular a plasmid, a 5 poxvirus or an adenovirus, as seen above. The subject of the invention is finally the use of phages expressing the peptide of interest or a combination of phages expressing the peptides of interest as a diagnostic reagent or as an antigenic or 10 vaccine component. The invention also relates to the use of at least one peptide in accordance with the invention in combination or otherwise with at least one recombinant vector in accordance with the invention for the 15 preparation of a pharmaceutical composition intended for preventing or curing an HIV virus-related condition. A composition according to the invention may comprise preparations which may be in the form of creams, powders which are freeze-dried or otherwise, 20 solutions, suspensions, for administrations by the mucosal route such as the oral, nasal, rectal, genital or cutaneous route for example. For parenteral administrations such as intradermal, subcutaneous, intramuscular, intravenous, intraarterial, 25 intralymphatic or intraperitoneal administration, for example, the sterile injectable preparations may be, depending on the cases, in the form of solutions, suspensions or emulsions. In addition to the active ingredient (s) , in accordance with the subject of the 30 invention, the preparations may contain excipients and/or stabilizing agents suited to the mode of administration. The preparations intended for a vaccine use may also contain adjuvants or be incorporated into delivery 35 systems compatible with a use in human medicine. There may be mentioned in particular the use of adjuvants such as Alum (aluminum phosphate or hydroxide or the mixture of the two) conventionally incorporated into vaccines, incomplete Freund’s adjuvant, mono- – 14 phosphorylated lipid A (MPL), QS21, Polyphosphazene, muramyl dipeptide (MDP) or its derivatives, the use of a system for delivering the antigen such as the emulsions (MF59, SAF1, RIBI, SB 62, SB 26), ISCOMS, 5 liposomes, microspheres composed of PLGA polymers having a well calibrated diameter, or optionally pseudovirions. The doses and routes for administration of these pharmaceutical compositions will be determined 10 taking into account the nature of the composition, the level of expression of the peptide of interest by the recombinant vector if it is included in the preparation, the age, sex and weight of the individual receiving the preparation. Account will also be taken 15 of the relative importance of the carrier molecule in the conjugate if it is included in the composition. Taking into account all these factors which are known and recognized by persons skilled in the art, the peptide doses administered may be up to 1 to 5 mg but 20 more generally will be between 5 pg and 1 mg per injection, preferably 50 to 500 gg. The recombinant vector encoding the peptide of interest may be administered or used to transfect or infect the cells of interest at a minimum dose of 103’5 infectious units 25 (pfu or plaque forming unit). Preferably, the recombinant vector will be used in a dose range going from 104 to 1010 pfu depending on the efficiency of expression of the peptide by this vector and in particular in a dose range going from 106 to 109 pfu, 30 for example. When the pharmaceutical composition comprises several recombinant vectors encoding different peptides of interest, it is clearly understood that these same ranges of doses may be applied to these combinations. Persons skilled in the 35 art will be able to refer to the clinical protocols and trials using preparations based on recombinant vectors, in particular recombinant poxviruses or recombinant adenoviruses, already carried out in humans in order to
II,
– 15 agree on the appropriate number of pfu which the pharmaceutical composition should contain. When the pharmaceutical composition comprises a plasmid containing the system for expressing the 5 peptide of interest, account will be taken, in dosing this composition, of the level of immune response which this composition is capable of inducing, which should be at least equal to that of the intact or modified peptide and/or of the level of expression of the 10 peptide induced by the plasmid in the cells of the body which should be as close as possible to that obtained by the recombinant vectors already mentioned. For example, the quantities of plasmids contained in the pharmaceutical compositions may be in ranges going from 15 1 Rg to 100 mg, preferably between 0.1 mg to 10 mg. Persons skilled in the art will be able to refer to the clinical protocols and trials already carried out in humans, using plasmid DNA preparations in order to agree on the plasmid dose which the pharmaceutical 20 composition should contain. For the prevention of HIV infection, the pharmaceutical composition may be administered in a single dose or in divided doses in order to reach the desired level of response comprising in particular the 25 level and the quality of the specific antibody and/or specific cell-mediated response desired, and characterized in that it ensures protection of the individual against accidental infection. To achieve this objective, it may be necessary, in addition to the 30 composition of the preparation and the route of administration chosen, to observe the periods allowed between each injection, which may be preferably 1 month, 2 months or 6 months and/or to use in combination or alternately for the duration of the 35 medical, in particular vaccine, protocol different pharmaceutical compositions relating to the peptide, to the recombinant vector, to the plasmid of interest or even to the phages expressing the peptide(s) of interest which persons skilled in the art are capable – 16 of controlling. It may also be necessary, in order to maintain the level of protection, to perform booster injections at regular intervals. For the treatment of HIV-related infection, the 5 pharmaceutical, in particular vaccine, composition may be administered in a single dose or in divided doses and at intervals which may be very short, in particular within periods of less than one week, in order to reach the desired level of response, in particular that which 10 makes it possible to observe the absence of the HIV virus in the blood by the PCR test. If necessary, the pharmaceutical composition comprising the peptide, the vector, the plasmid of interest or even the phages expressing the peptide(s) of interest may be combined 15 or used alternately with the conventional treatments for this condition, comprising in particular antiviral mono-, bi- or tritherapy. Whether for the prevention or the treatment of HIV infection, it may also be useful to use a 20 pharmaceutical composition comprising one or more peptides of interest, the corresponding recombinant vector(s) of interest as well as the plasmid(s) of interest or even the bacteriophages expressing the peptide(s) of interest in order to stimulate the cells 25 of the immune system of the patient in vitro or ex vivo and to then reinject them into the body of the individual. This method was in particular developed in the immunotherapeutic treatment of cancer. The subject of the invention is finally the use 30 of the peptides of interest as reagent for the diagnosis of HIV infection which makes it possible in particular to identify subjects more resistant to the infection also called “long-term nonprogressors” or on the contrary to identify the infected subjects more 35 likely to rapidly develop AIDS. For the first time, novel conformational epitopes of the HIV envelope have been defined. These peptides can therefore be used, for 7 RA4 diagnostic purposes, to preferably test for Iz neutralizing antibodies for primary HIV isolates, which It, – 17 very often recognize conformational epitopes and thus make it possible to distinguish the “long-term nonprogressor” individuals (possessing neutralizing antibodies) from those which are likely to rapidly 5 develop AIDS if no treatment, in particular antiviral treatment, is rapidly introduced (possessing no neutralizing antibodies). The subject of the present invention is therefore also a method for the diagnosis of HIV 10 infection and/or of susceptibility of infected subjects to rapidly develop AIDS, said method being preferably based on the analysis of the humoral response. For the analysis of the humoral response, immunoenzymatic, radioimmunological or Western blotting methods which 15 are well known to persons skilled in the art, such as for example the ELISA, RIA, RIPA or IRMA methods, may be used. Description of the figures Figures 1 to 5 represent, as a function of 20 their dilution, the curves for the binding of phages respectively expressing the peptide sequences SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 to a recombinant antibody specific for Ggp 160 and derived from the combinatorial antibody 25 library produced from lymphocytes of a “long-term nonprogressor” subject (M) and to an antibody IgG not specific for the HIV envelope antigen (@), these two antibodies being previously bound to ELISA plates. The intensity of the binding is proportional to the optical 30 density (OD) value obtained by ELISA. The present invention is described in greater detail below with the aid of the additional description which follows, which refers to examples of selection of antibodies directed against the HIV envelope, selection 35 of peptides according to the invention, synthesis of peptides according to the invention, induction of antibodies specific for peptides according to the invention, vaccine compositions according to the invention and use of peptides according to the – 18 invention for the diagnosis of HIV infection. It goes without saying, however, that these examples are given by way of illustration of the subject of the invention and do not in any manner constitute a limitation 5 thereto. Example 1: Selection of peptides The manufacture of recombinant antibodies using molecular biology methods have developed substantially over the last ten years and are now well known to 10 persons skilled in the art. It is also known that the specificity of a recombinant antibody is essentially carried by the CDR3s of the light and heavy chains. Knowledge of the amino acid linkage which represents CDR3 and of the structure of the backbone of the heavy 15 and light chains of a given antibody is sufficient for persons skilled in the art to be able to reproduce and reconstitute an equivalent recombinant antibody having the same characteristics of recognizing said antibody. The sequences encoding the portions of heavy 20 and light chains of the Fab molecules selected may be isolated and synthesized, and cloned into any vector or replicon allowing their expression. Any appropriate expression system may be used, for example bacteria, yeasts, insect, amphibian and 25 mammalian cells. The systems for expression in bacteria include those described in Chang et al. (1978) Nature 275: 615, Goeddel et al. (1979) Nature 281: 544, Goeddel et al. (1980) Nucleic Acids Res. 8: 4057, EP-A-36,776, US-A-4,551,433, deBoer et al. (1983) Proc. 30 Natl. Acad. Sci. USA 80: 21-25, and Siebenlist et al. (1980) Cell 20: 269. The systems for expression in yeasts include those described in Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75: 1929, Ito et al. (1983) J. Bacteriol. 153: 163, Kurtz et al. (1986) Mol. Cell. 35 Biol. 6: 142, Kunze et al. (1985) J. Basic Microbiol. 25: 141, Gleeson et al. (1986) J. Gen. Microbiol. 132: 3459, Roggenkamp et al. (1986) Mol. Gen. Genet. 202: 302, Das et al. (1984) J. Bacteriol. 158: 1165, De Louvencourt et al. (1983) J. Bacteriol. 154: 737, Van R 4i – 19 den Berg et al. (1990) Bio/Technology 8: 135, Kunze et al. (1985) J. Basic Microbiol. 25: 141, Cregg et al. (1985) Mol. Cell. Biol. 5: 3376, US-A-4,837,148 and 4,929,555, Beach et al. (1981) Nature 300: 706, Davidow 5 et al. (1985) Curr. Genet. 10: 380, Gaillardin et al. (1985) Curr. Genet. 10: 49, Ballance et al. (1983) Biochem. Biophys. Res. Commun. 112: 284-289, Tilburn et al. (1983) Gene 26: 205-221, Yelton et al. (1984) Proc. Natl. Acad. Sci. USA 81: 1470-1474, Kelly et al. (1985) 10 EMBO J. 4: 475479; EP-A-244,234 and WO-A-91/00357. The expression of hetetologous genes in insects may be carried out as described in US-A-4,745,051, EP-A-127,839 and EP-A-155,476, Vlak et al. (1988) J. Gen. Virol. 69: 765-776, Miller et al. (1988) Ann. Rev. 15 Microbiol. 42: 177, Carbonell et al. (1988) Gene 73: 409, Maeda et al. (1985) Nature 315: 592-594, Lebacq Verheyden et al. (1988) Mol. Cell. Biol. 8: 3129, Smith et al. (1985) Proc. Natl. Acad. Sci. USA 82: 8404, Miyajima et al. (1987) Gene 58: 273, and Martin et al. 20 (1988) DNA 7: 99. Numerous strains and variants of baculoviruses and permissive insect cells are described in Luckow et al. (1988) Bio/Technology 6: 47-55, Miller et al. (1986) GENERIC ENGINEERING, Setlow, J.K. et al. Eds. Vol. 8, Plenum Publishing pp. 277-279, and Maeda 25 et al. (1985) Nature 315: 592-594. The expression in mammalian cells may be carried out as described in Dijkema et al. (1985) EMBO J. 4: 761, Gorman et al. (1982) Proc. Natl. Acad. Sci. USA 79: 6777, Boshart et al. (1985) Cell 41: 521, and US-A-4,399,216. Reference 30 may also be made to Ham et al. (1979) Meth. Enz. 58: 44, Barnes et al. (1980) Anal. Biochem. 102: 255, US-A-4,767,704, 4,657,866; 4,927,762; 4,560,655; US patent RE 30,985, WO-A-90/103430 and WO-A-87/00195. The peripheral blood lymphocytes obtained from 35 a subject who has been infected with the HIV virus and who belongs to the “long-term nonprogressor” group are used to produce the combinatorial antibody library. The cDNA of the lymphocytes is obtained from the RNA using a method developed by Sodoyer R. et al. (1997) Human -4 – 20 Antibodies 8: 37. The heavy and light chain library is constructed using the phagemids pVH (pM 831) and pVL (pM452). The two libraries are then combined in a “Random” manner by subcloning the VL genes into the 5 heavy chain library. The phagemid library obtained is then infected with the helper phage M13 VCS thus allowing the expression of the Fab’s at the surface of the phages. After selection of the phages expressing the Fab’s at their surface by “panning” against the 10 Gp 160 protein, the nucleotide sequence of the recombinant Fab’s expressed by the positive isolates and in particular the CDR3 sequences carried by the fragments of heavy and light chains, is determined. One of the recombinant antibodies specific for 15 Gp 160 obtained from this combinatorial library is then used to select the peptide sequences SEQ NO: 1 to SEQ NO: 11 from a commercially available phage library randomly expressing peptides (pHD7, NEB) by carrying out the procedure in the following manner: 20 1.4 x 1011 phages are incubated with 30 or 300 ng of the recombinant antibody according to example 1 in 200 pl of PBS-0.1% tween 20 for 20 min at 20 0 C. The mixture is transferred into a tube containing 50 sl of G protein coupled to sepharose beads previously equilibrated for 25 1 hour in 1 ml of PBS-0.1% tween 20 containing 5% of skimmed milk. After another incubation of 20 min, the beads are centrifuged and washed 3 times with 1 ml of PBS-0.1% tween 20. On the 4th washing, the beads are taken up in PBS-0.1% tween 20 containing 5% of skimmed 30 milk, incubated for 10 min, centrifuged and rinsed again 3 times with PBS-0.1% tween 20. After the last centrifugation, the beads are taken up in 1 ml of 0.2 M glycine-HC1, pH = 2.2, incubated for 10 min at 20 0 C and centrifuged. The supernatant is transferred into a tube 35 containing 60 pl of 2 M Tris base, pH = 7.5, so as to neutralize the solution and then incubated with 2 ml of E. coli 7118 bacteria in the exponential growth phase for 15 min. The culture volume was adjusted to 100 ml with LB medium, and the incubation was continued for – 21 4 h at 37 0 C. After a centrifugation intended to remove the bacteria, the phages are precipitated by addition of 25 ml of 20% PEG-2.5 M NaCl in the culture supernatant overnight at 40C. After centrifugation 5 (10 000 rpm, 20 min, 40C), the phage pellet is taken up in 1 ml of PBS-0.1% tween 20-1% skimmed milk, and the titer determined. The screening is complete when the whole process has been repeated 3 to 4 times. To complete the selection of the phages 10 expressing the peptide sequences 1 to 11, they were also tested by ELISA as follows: 0.2 mg of recombinant antibody specific for Gp 160 or of antibody which has no specificity for an antigen of the HIV envelope called “Ig control”, diluted in 50 pl 15 of PBS, is deposited in each well of an ELISA plate followed by incubation overnight at 40C. After replacing the antibody solution with 0.1 ml of PBS-0.1% tween 20 (PBST) containing 5% of skimmed milk and incubating for 1 h at 370C, and preparing a 2-fold 20 serial dilution on the phages expressing the peptide sequences SEQ ID NO: 1 to SEQ ID NO: 11 in PBST-l% skimmed milk, the various dilutions prepared are distributed into the wells sensitized either with the specific recombinant antibody according to example 1, 25 or with the Ig control. After 2 h at 37 0 C, the phages are removed by aspiration of the dilutions and then the wells are washed 10 times with 0.2 ml of PBST. The wells are then incubated for 1 h at 370C with a 1:1000 solution in PBST-1% milk of a biotinylated antibody 30 directed against the phage fd (SIGMA) . After another series of washes in PBST-l% milk, a streptavidin peroxidase (SIGMA) complex diluted to 1:2000 in PBST is added to each well, followed by incubation for 1 h at room temperature and washes in PBST-1% milk. The 35 enzymatic activity of peroxidase is conventionally visualized by addition of an OPD solution diluted to 1 mg/ml in sodium citrate buffer. The intensity of the color of the OPD solution is then measured on a spectrophotometer, and then the OD (optical density) Lu – 22 curves are established as a function of the phage dilution. The curves of figures 1 to 5 show, by way of example, that the phages expressing the peptide sequences SEQ ID NO: 7 to SEQ ID NO: 11 indeed bind to 5 the specific recombinant antibody (OD > 0.6 observed for at least one phage dilution) whereas there is no significant binding to the Ig control (OD 0.3 whatever the phage dilution tested in the dilution series going from 5 x 1011 phages/well to 4.8 x 108 10 phages/well). The positive phages, that is to say those which bind specifically to the specific recombinant antibody are amplified in E. coli. Mini preparations of phage DNA are prepared according to the procedures described in the manuals by Maniatis, the DNA is 15 sequenced with the aid of an automated sequencer from which the sequence of the peptide expressed by the phage is deduced. Example 2: Synthesis of peptides The peptides of SEQ ID NO: 1 to SEQ ID NO: 11 20 are synthesized in solid phase by referring to the methods developed in the manuals Solid phase peptide synthesis: a practical approach, IRL Press, Oxford, 1989 and Solid phase peptide synthesis, second edition, published by Pierce Chemical Company, 1984. 25 The a-amino function of the amino acids is protected by introducing a t-butyloxycarbonyl (t-boc) group thus allowing coupling through the carboxyl function of the amino acid to an active chloro methylated resin. After binding to the resin, the amine 30 function is “deprotected” by the action of trifluoroacetic acid followed by a step of neutralizing with triethylamine. The amine function thus released then undergoes a reaction for coupling with another amino acid in the form of a t-boc derivative via 35 carbodiimides. This method is used by the ABI (Applied Biosystem Inc) 430A automated device which thus performs the automated synthesis of peptides. At the end of the synthesis, the peptide is detached from the resin by the action of hydrofluoric acid. The extract – 23 is then purified by reversed-phase HPLC using a semipreparative column of the Vydac C4 type and an acetonitrile gradient ranging from 15 to 55% in a 0.1% trifluoroacetic acid solution. Liquid chromatography is 5 programed for a period of 40 min with a flow rate of 2 ml/min. The level of purity of the peptides is checked by analytical chromatography and exceeds 95%. Example 3: Induction of specific antibodies 1) Induction of antibodies in guineapigs and rabbits 10 The peptides of SEQ ID NO: 1 to 6, presented on phages, are injected into guineapigs and rabbits: 2 injections of 100 microliters by the intravenous route, at an interval of 3 weeks followed by a final bleeding 15 days after the 2nd injection. The sera are 15 tested by ELISA against gp160 and a reaction is observed against the glycoprotein. These peptides are therefore capable of inducing a response against gp160. 2) Induction of antibodies in mice The various isolates of phages expressing the 20 peptides defined by SEQ ID NO: 7 to SEQ ID NO: 11 are purified on a cesium chloride gradient. 5 groups of BaLB/c mice were then identified. Each group was immunized by the intraperitoneal route, 3 times at an interval of 3 weeks with only one type of purified 25 isolate expressing either SEQ ID NO: 7 or SEQ ID NO: 8 or SEQ ID NO: 9 or SEQ ID NO: 10 or SEQ ID NO: 11 at the rate of 1012 purified phages per injection. To compare the antibody responses, we introduced 2 groups of additional mice, the first group receiving 30 3 injections of 1012 phages expressing peptides not mimicking conformational epitopes of the HIV envelope (irrelevant phages), the second receiving 3 injections of 5 gg of Gp160 protein. We also introduced an 8th group of mice which received a mixture of phage 35 isolates, comprising, in equal parts, phages expressing SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11. A few mice in this group as well as RA few mice in the group immunized with the irrelevant phages received a 4th injection of 5 gg of Gp 160, 3 4u – 24 weeks after the 3rd injection. The analysis of the specific antibody response is performed on the serum of the mice in each group collected 15 days after each injection. The analysis of the specific antibody 5 response comprises the detection of anti-gp 160 antibodies by ELISA with the aid of plates sensitized with the Gp 160 protein using a procedure similar to that described in example 1 and the test for neutralizing antibodies. For the test for neutralizing 10 antibodies, the serum dilution which prevents the formation of syncytia in 50% of the microwells infected with 10 CCID 50 of an HIV virus strain is determined. After decomplementizing the sera and preparing a 2-fold serial dilution in RPMI medium, 500 pl of the HIV virus 15 suspension titrating 102.5 CCID 5 o/ml are mixed with 500 pl of various dilutions of sera. After incubating for 2 hours at 37 0 C, the mixture is deposited in a volume of 100 pl on CEMss cells previously attached in microwells (6 microwells/dilution of serum). After 20 1 hour of contact at 37 0 C with the CEMss cells, the mixture is aspirated and replaced with culture medium. After 7 and 14 days of incubation, the cultures are examined under a microscope for the enumeration of the syncytia. The titer neutralizing by 50% is determined 25 according to the Spearman and Karber method. A good production of antibodies is observed in the mice in the 8th group which was immunized with the mixture of isolates of phages expressing the various peptide sequences (SEQ ID NO: 7 to SEQ ID NO: 11) 30 Example 4: Vaccine formulations A peptide having one of the sequences SEQ ID NO: 1 to SEQ ID NO: 11 described in example 1 and produced by chemical synthesis according to example 2 or obtained from the product of expression of a 35 recombinant vector and in particular of a recombinant baculovirus using the techniques developed by Smith et RA4’ al (USA 4, 745, 051) . Water-in-oil emulsions were then prepared using squalene as constituent of the organic phase, tween 80 or a mixture of tween 80 and SPAN as
‘U,-
– 25 surfactant, the aqueous phase containing the peptide solution. When the hydrophobicity of the peptide is very high, oil-in-water emulsions are prepared in which the peptide will be associated with the organic phase. 5 If necessary, immunostimulants such as QS 21, derivatives of MPL, or any other adjuvant are incorporated into the preparation of these emulsions. This formulation is used for the preparation of a vaccine composition intended for the prevention or 10 treatment of HIV virus infection. Example 5: Vaccine formulations A vaccine formulation based on liposomes is prepared which comprises a peptide having one of the sequences SEQ ID NO: 1 to SEQ ID NO: 11 described in 15 example 1 and produced by chemical synthesis according to example 2 by reference to manuals such as “Liposomes as Drug Carriers” published by G. Gregoriadis, 1988, or to volumes 1 to 3 of “Liposome Technology published by G. Gregoriadis, 1984. This formulation is used for the 20 preparation of a vaccine composition intended for the prevention or treatment of HIV virus infection. Example 6: Vaccine formulations A vaccine formulation based on ISCOMs is prepared which contains a peptide having one of the 25 sequences SEQ ID NO: 1 to SEQ ID NO: 11 described in example 1 and produced by chemical synthesis according to example 2 by reference to B Morein et al, 1984, Nature 308:457 or B Morein et al Immunology toDay, 1987, 8(11):333. 30 Example 7: Vaccine formulations A formulation based on microparticles is prepared which comprises a peptide having one of the sequences SEQ ID NO: 1 to SEQ ID NO: 11 described in example 1 and produced by chemical synthesis according 35 to example 2 mimicking a conformational epitope of the HIV envelope. For the preparation of microparticles or of nanoparticles, many synthetic or natural polymers are used such as the methyl metacrylate polymer (Troster S.D. et al, 1992, J. Microencaps. 9:19) but – 26 of ten poly (d, 1-lactide-co-glycolide) also called PLGA is the referent because of its biodegradability, its safety and its already old applications in the medical field. The microparticles of PLGA, loaded with 5 peptides, are prepared in particular by a water-in-oil in-water double emulsion. The peptide is solubilized in aqueous phase and then emulsified in a solution of PLGA in the organic phase such as dichloromethane. The water-in-oil emulsion is obtained by stirring the 10 peptide solution at high speed in the organic solution of PLGA. A second aqueous phase containing an appropriate concentration of surfactant such as polyvinyl alcohol is then added to the first emulsion in order to thus produce the double emulsion. Other 15 surfactants are also used such as bile salts or poly(oxyethylene glycerol monoleate) in order to stabilize the double emulsion (Rafati H et al., 1997, Vaccine 15: 1888). After stirring overnight in order to allow evaporation of the solvent, the microparticles of 20 PLGA are washed several times in distilled water and then freeze-dried and stored at 5 0 C. This formulation is used for the preparation of a vaccine composition intended for the prevention or treatment of HIV virus infection. 25 Example 8: Vaccine composition The peptides which contain less than 20 amino acids may be weakly immunogenic. To increase the immunogenicity of the peptides having one of the sequences SEQ ID NO: 1 to SEQ ID NO: 11 described in 30 example 1 and produced by chemical synthesis according to example 2, a vaccine formulation is prepared which is based on polymers of the same peptide or of different peptides, in the form of octamers comprising a branched polylysine structure containing 8 side arms 35 onto which the same peptide or different peptides according to example 1 are attached using the method developed by Posnett D.N et al. (1988) J. Biol. Chem. 263: 1719. This formulation is used for the preparation 7), – 27 of a vaccine composition intended for the prevention or treatment of HIV virus infection. Example 9: Vaccine composition A vaccine composition is prepared which 5 comprises a peptide having one of the sequences SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 4 described in example 1 and produced by chemical synthesis according to example 2, according to example 2 flanked by the 2 helper T epitopes P24E and T of the HIV virus, these 2 10 epitopes playing the role of carrier molecule and thus enhancing the immunogenicity of the peptide. The reaction for coupling the peptide to these 2 helper T epitopes occurs in 2 stages according to conventional methods well known to persons skilled in the art. In a 15 first stage, the coupling of the N-terminal portion of the peptide with the C-terminal portion of the peptide sequence representing the epitope p24E is carried out by intercalating a spacer consisting of the glycine proline-glycine sequence. In a second stage, the 20 coupling of the C-terminal portion of the intermediate product with the N-terminal portion of the peptide sequence representing the Tl epitope is then carried out by intercalating the same glycine-proline-glycine sequence in order to obtain the final product. This 25 formulation is used for the preparation of a vaccine composition intended for the prevention or treatment of HIV virus infection. Example 10: Vaccine composition comprising a lipopeptide 30 A vaccine formulation is prepared which comprises a peptide having one of the sequences SEQ ID NO: 1 to SEQ ID NO: 11 described in example 1 and produced by chemical synthesis according to example 2 coupled to one or more chains among derived from fatty 35 acids, which NE-palmitoyllysine, N,N-dipalmitoyllysine, pimelautide, trimexautide or to a steroid group among which N [(cholest-5-enyl-3-oxy)acetyl) ]lysine or (cholest-5-enyl-3-oxy)acetic acid according to the method described in patent EP0491628 (INSERM) so as to – 28 obtain a lipopeptide. This formulation is used for the preparation of a vaccine composition intended for the prevention or treatment of HIV virus infection. Example 11: Expression of the peptides by poxviruses 5 A vaccine composition is prepared which comprises a recombinant poxvirus encoding a peptide having one of the sequences SEQ ID NO: 1 to SEQ ID NO: 11 described in example 1 mimicking a conformational epitope of the HIV envelope. The 10 recombinant poxviruses are obtained by homologous recombination from chicken embryo cells infected with the poxviruses and cotransfected with plasmids containing an expression cassette, flanked at the ends with DNA sequences homologous to those of nonessential 15 regions of the poxvirus DNA, and containing, under the control of poxvirus promoters (H6, 13L), the polynucleotide which encodes the peptide according to example 2 using the methods described in patents US 4,769,330, 4,772,848, 4,603,112, 5,100,587, 5,179,993 20 and 5,863,542. These recombinant poxviruses are used for the preparation of a vaccine composition intended for the prevention or treatment of HIV virus infection. Example 12: Expression of several peptides by a poxvirus 25 A vaccine composition is prepared which comprises a recombinant poxvirus encoding several peptides having one of the sequences SEQ ID NO: 1 to SEQ ID NO: 11 described in example 1 mimicking several conformational epitopes of the HIV envelope. The use 30 and the preparation of recombinant vectors encoding several epitopes is well known to persons skilled in the art (Toes RE et al. (1997) Proc. Natl. Acad. Sci. USA 94: 14660, Thomson SA et al. (1996) J. Immunol. 157: 822) and is also applicable to the preparation of 35 recombinant poxviruses encoding multiple mimotopes. A vaccine composition is in particular prepared which comprises a recombinant canaripox (recombinant ALVAC) encoding multiple mimotopes of the HIV envelope. These recombinant poxviruses are used for the preparation of 4, – 29 a vaccine composition intended for the prevention or treatment of HIV virus infection. Example 13: Combinations of peptides A vaccine composition is prepared which 5 comprises several peptides having one of the sequences SEQ ID NO: 1 to SEQ ID NO: 11 described in example 1 using the various modes of preparation described in examples 2 to 12 mimicking several conformational epitopes of the HIV envelope. These various 10 compositions are used for the preparation of a vaccine composition intended for the prevention or treatment of HIV virus infection. Example 13: Diagnosis A detection of antibodies specific for HIV is 15 carried out by ELISA using one or more peptides having one of the sequences SEQ ID NO: 1 to SEQ ID NO: 11 described in example 1 and produced by chemical synthesis according to example 2 for the diagnosis of HIV infection using a biological sample as starting 20 material. In general, a sample of physiological fluid (blood, plasma, serum) is collected, which sample is then caused to react in the presence of a peptide according to the invention. To do this, the peptide itself is used as diagnostic 25 reagent. Use is generally made of – either an indirect diagnostic test, of the ELISA type, in which the peptide attached to a support (well) is brought into contact with the sample to be tested, while the visualization of the antigen-antibody 30 attachment is produced by a labeled anti-Ig. – or a competition or displacement test in which a peptide according to the invention, and a labeled antibody specific for the peptide are used. The peptide is also attached to a solid support such as wells or 35 strips. In the competition test, the peptide is simultaneously brought into contact with the sample (antibody of the sample) and with a labeled antibody TRAg 1 specific for the peptide. Peroxidase-labeled antibodies are generally used.
– 30 In the competition or displacement test, monoclonal or polyclonal antibodies or recombinant antibodies specific for the peptide according to the invention, which are sometimes Fab or F(ab) 2 fragments and in 5 particular those described in the invention, are generally used. Example 14: Diagnosis A detection of antibodies specific for HIV is carried out by immunochromatography using one or more 10 peptides according to the invention for the diagnosis of the HIV infection using a biological sample as starting material. In this case, the peptide according to the invention is attached to a support of the strip type and reference 15 is made to the article by Robert F.N Zurk et al., Clin. Chem. 31/7, 1144-1150 (1985) as well as to patents or patent applications WO-A-88/08 534, WO-A-91/12528, EP-A-291 176, EP-A-299 428, EP-A-291 194, EP-A-284 232, US-A-5 120 643, US-A-5 030 558, US-A-5 266 497, US-A-4 20 740 468, US-A-5 266 497, US-A-4 855 240, US-A-5 451 504, US-A-5 141 850, US-A-5 232 835 and US-A-5 238 652 in order to carry out the method. Example 15: Diagnosis 25 Study of the lymphoproliferative response specific to one or more peptides according to the invention for the diagnosis of HIV virus infection using a biological sample as starting material. The patient’s blood is collected on a heparinized tube. 30 The lymphocytes are then separated by centrifugation on Ficoll hypaque and then distributed into sterile 96-well microplates at the rate of 2 x 105 cells per round-bottomed well in a final volume of 200 pl of complete culture medium (RPMI 1640 supplemented with 35 25 mM HEPES, 2 mM L-glutamine, 50 U/ml of penicillin, 50 pg/ml of streptomycin and 5% of decomplementized AB serum) and brought into contact with variable RAg/ concentrations of one or more peptides having one of I the sequences SEQ ID NO: 1 to SEQ ID NO: 11 described
)C)
– 31 in example 1 and produced by chemical synthesis according to example 2 (concentrations ranging from 1 ng/ml to 50 gg/ml). Each peptide concentration is tested in triplicate so as to better eliminate the 5 biological variations. Multiple combinations of peptides may also be tested in the concentration range indicated, for example a combination resulting from the association of a mimotope of the envelope with a mimotope of the nucleocapsid in the concentration range 10 indicated. After 5 days of culture at 370C under 5% C02, 0.5 pci of tritiated thymidine is added to each well. After another incubation of 16 hours, the cellular DNA of each culture well is recovered on filters after ethanol precipitation and the rate of 15 incorporation of tritiated thymidine is measured with the aid of a liquid scintillation counter which reflects the intensity of the lymphoproliferative response. The results are expressed in the form of a stimulation index (mean of the cpm values for the 20 lymphocyte culture wells containing a given concentration of peptide/mean of the cpm values for the lymphocyte culture wells without peptide). The lymphoproliferative response is considered to be positive when the stimulation index is greater than 3.

Claims (19)

1. Peptide for the prevention or therapeutic treatment of HIV virus infection capable of interacting with an antibody specific for an antigen of the 5 envelope of said virus and obtained from an HIV positive patient belonging to the “long-term nonprogressor” group, comprising an amino acid sequence which mimics a conformational epitope of an antigen of said envelope without, however, corresponding to a 10 continuous amino acid sequence of this antigen.

2. Peptide according to claim 1, according to which the antigen of the envelope is represented by the envelope protein gp160.

3. Peptide according to claim 1 or 2, 15 characterized in that this peptide may comprise the sequences 1 to 11 SEQ ID NO: 1 Phe Asn Leu Thr His Phe Leu SEQ ID NO: 2 Glu Gly Trp His Ala His Thr SEQ ID NO: 3 Lys Leu Asn Trp Met Phe Thr 20 SEQ ID NO: 4 Ser Thr Asn Trp Met Phe Thr SEQ ID NO: 5 Ala Met Pro Leu Pro Tyr Thr Phe SEQ ID NO: 6 Asp Ser His Thr Pro Gln Arg SEQ ID NO: 7 Val Ser Phe Thr Pro Ser Phe SEQ ID NO: 8 His Ala Ala Leu Ser Met Asn Thr His Ala Leu Met 25 SEQ ID NO: 9 Ala Trp His Glu Ser Arg Ala SEQ ID NO: 10 Phe Lys Thr Ala Tyr Pro Thr SEQ ID NO: 11 Ser His Ala Leu Pro Leu Thr Trp Ser Thr Ala Ala

4. Peptide comprising the linkage of at least two peptides according to one of claims 1 to 3. 30

5. Peptide according to claim 4, comprising the duplication of identical peptides.

6. Peptide according to claim 5, in which the coupling of the two peptides occurs by means of a “spacer” arm consisting of the amino acid sequence Gly 35 Pro Gly

7. Conjugate comprising at least one peptide according to one of claims 1 to 6, bound to a carrier – 33 molecule in order to induce or enhance the immunogenicity of said peptide.

8. Conjugate according to claim 7, according to which the carrier molecule comprises at least one 5 helper T epitope of the HIV virus.

9. Conjugate according to claim 8, whose carrier molecule comprises the p24E and Ti epitope of the HIV virus

10. Conjugate according to claim 9, comprising a 10 peptide resulting from the duplication of the sequences NO: 1, NO: 3 or NO: 4 according to claim 6, said peptide being bound on the N-terminal side to the p24E epitope and on the C-terminal side to the Ti epitope by means of 2 “spacer” arms. 15

11. Conjugate according to claim 10, characterized in that the 2 spacer arms are identical and consist of the linkage Gly Pro Gly and in that it comprises any one of the sequences 12 to 14 SEQ ID NO: 12 Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg 20 Phe Tyr Lys Gly Pro Gly Lys Leu Asn Trp Met Phe Thr Gly Pro Gly Lys Leu Asn Trp Met Phe Thr Gly Pro Gly Iys Gln Ile Ile Asn Met Trp Gln Glu Val Glu Lys Ala Met Tyr Ala 25 SEQ ID NO: 13 Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Gly Pro Gly Ser Thr Asn Trp Met Phe Thr Gly Pro Gly Ser Thr Asn Trp Met Phe Thr Gly Pro Gly Iys Gln Ile Ile Asn Met Trp Gln Glu Val Glu Lys Ala Met Tyr Ala 30 SEQ ID NO: 14 Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Gly Pro Gly Phe Asn Leu Thr His Phe Leu Gly Pro Gly Phe Asn Leu Thr His Phe Leu Gly Pro Gly Lys Gln Ile Ile Asn Met Trp Gln Glu Val 35 Glu Lys Ala Met Tyr Ala

12. Recombinant vector comprising a functional expression cassette allowing the expression of a – 34 polynucleotide encoding a peptide according to one of claims 1 to 11

13. Recombinant vector according to claim 12, characterized in that it is an adenovirus, a poxvirus, 5 a baculovirus, a bacteriophage or a plasmid.

14. Therapeutic or prophylactic composition for HIV infection, in particular intended for vaccine use, whose active ingredient comprises a peptide according to one of claims 1 to 11 and/or a recombinant vector 10 encoding said peptide according to either of claims 12 and 13.

15. Composition according to claim 14, whose active ingredient is in the form of a formulation combined with a compatible adjuvant for administration of an 15 effective dose by the mucosal or parenteral route.

16. Use of a peptide according to one of claims 1 to 11 and/or of a recombinant vector according to either of claims 12 and 13 as reagent for the diagnosis of HIV, said diagnosis comprising the evaluation, from 20 a blood sample, of the humoral and/or cell-mediated response specific for this peptide.

17. Use of a peptide according to one of claims 1 to 11 and/or of a recombinant vector according to either of claims 12 and 13 as reagent for the diagnosis 25 of the susceptibility of subjects infected with the HIV virus to rapidly develop AIDS.

18. Use of a peptide according to one of claims 1 to 11 and/or of a recombinant vector according to either of claims 12 and 13 for the preparation of a 30 therapeutic or prophylactic composition intended for the treatment or prevention of HIV infection.

19. Use of a peptide according to one of claims 1 to 11 and/or of a recombinant vector according to either of claims 12 and 13 for stimulating in vitro 35 cells of the immune system of an individual, said cells then being intended to be reinjected into the body of the individual after stimulation.

AU41489/99A
1998-06-12
1999-06-14
HIV virus mimotopes

Ceased

AU748700B2
(en)

Applications Claiming Priority (3)

Application Number
Priority Date
Filing Date
Title

FR9807598

1998-06-12

FR98/07598

1998-06-12

PCT/FR1999/001409

WO1999066046A1
(en)

1998-06-12
1999-06-14
Hiv virus mimotopes

Publications (2)

Publication Number
Publication Date

AU4148999A
true

AU4148999A
(en)

2000-01-05

AU748700B2

AU748700B2
(en)

2002-06-13

Family
ID=9527466
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU41489/99A
Ceased

AU748700B2
(en)

1998-06-12
1999-06-14
HIV virus mimotopes

Country Status (5)

Country
Link

EP
(1)

EP1084253A1
(en)

AU
(1)

AU748700B2
(en)

CA
(1)

CA2331197A1
(en)

NZ
(1)

NZ508812A
(en)

WO
(1)

WO1999066046A1
(en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

EP1159297A2
(en)

1999-01-11
2001-12-05
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
Hiv related peptides

US6911527B1
(en)

1999-01-11
2005-06-28
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services
HIV related peptides

FR2818648B1
(en)

2000-12-22
2003-10-10
Aventis Pasteur

PROTEIN ANTIGENS INDUCING HIV VIRUS NEUTRALIZING ANTIBODIES

AU2002219290A1
(en)

2000-12-22
2002-07-08
Aventis Pasteur
Proteinic antigens inducing antibodies neutralising hiv virus

CA2756570C
(en)

2009-04-17
2019-04-30
National Research Council Of Canada
Peptide ligands for clusterin and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

EP0702693A1
(en)

1993-06-09
1996-03-27
Connaught Laboratories Limited
Tandem synthetic hiv-1 peptides

ATE274578T1
(en)

1993-11-04
2004-09-15
Innogenetics Nv

HUMAN T CELL IMMUNODOMINANT EPITOPES OF THE C-HEPATITIS VIRUS

DE4405810A1
(en)

1994-02-23
1995-08-24
Behringwerke Ag

Peptides derived from a retrovirus from the HIV group and their use

US5877155A
(en)

1995-03-17
1999-03-02
The Research Foundation Of State University Of New York
Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX

DE19613253A1
(en)

1996-04-02
1997-10-09
Immuno Gmbh

Technique for the detection of infections with the TBE virus and other flaviviruses

WO1999012558A1
(en)

1997-09-10
1999-03-18
Allegheny University Of The Health Sciences
Inhibitors of collagen assembly

1999

1999-06-14
NZ
NZ508812A
patent/NZ508812A/en
unknown

1999-06-14
CA
CA002331197A
patent/CA2331197A1/en
not_active
Abandoned

1999-06-14
AU
AU41489/99A
patent/AU748700B2/en
not_active
Ceased

1999-06-14
EP
EP99925080A
patent/EP1084253A1/en
not_active
Withdrawn

1999-06-14
WO
PCT/FR1999/001409
patent/WO1999066046A1/en
not_active
Application Discontinuation

Also Published As

Publication number
Publication date

AU748700B2
(en)

2002-06-13

WO1999066046A1
(en)

1999-12-23

CA2331197A1
(en)

1999-12-23

EP1084253A1
(en)

2001-03-21

NZ508812A
(en)

2002-11-26

Contact information